Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Instagram Outage Disrupts Thousands of U.S. Users 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
MORRISVILLE, N.C., Aug. 03, 2017 -- Clinipace Worldwide, a global full-service clinical research organization (CRO), has launched a new regulatory and strategic development consultancy called RSD Global Consulting (RSDGC).
With more than 50 specialists, Clinipace RSD Global Consulting provides strategic consulting and regulatory support in the United States, Europe, and Asia Pacific. RSDGC offers stage-specific solutions for all phases of development, from non-clinical and clinical, through to marketing applications and post-marketing support. The group also provides all aspects of pharmaceutical development support, including chemistry, manufacturing, and controls (CMC) strategy; dossier preparation ; pre-approval inspection (PAI) preparation; GxP auditing for compliance in pre-clinical (GLP), clinical (GCP), manufacturing (GMP), medical/regulatory writing, strategic biostatistics and a quality assurance (QA) consultancy.
“Whatever the scale or complexity, RSD Global Consulting has the breadth and depth of technical, regulatory and quality expertise to take promising therapies from bench to bedside,” said Nikolas Burlew, who was recently appointed as Executive Vice President of RSD Global Consulting. “Our RSD Global Consulting team applies pragmatic approaches to the complex challenges of drug development, managing costs, quality, and deliverables to ensure that our clients’ goals are met.”
“We are delighted to launch this new consultancy in response to customer demand, especially amongst the early state biotech and pharma companies that we serve” said Clinipace President and CEO Jeff Williams. “We can work with companies of all sizes, from early-stage biotech firms, through to clinical stage and multinational. From traditional small molecules to advanced biologics, across the complete array of dosage forms and a wide range of therapeutic areas, we can help customers plan and advance their programs into the clinic, to regulatory approval and beyond.”
About Clinipace Worldwide
Clinipace Worldwide, a global full-service clinical research organization (CRO) serves the unique needs of venture-backed, mid-tier and strategic pharmaceutical, biotechnology and medical device firms, helping them advance drug candidates to deliver successful stakeholder and patient outcomes.
The company leverages extensive therapeutic knowledge, clinical trial expertise, and their proprietary eClinical platform TEMPO™ to support life science firms in achieving some of their most important goals: Executing regulatory strategies, optimizing clinical development timelines and completing high quality trials. Clinipace has completed more than 1,500 clinical trials and 1,500 regulatory and statistical consulting projects and operates in North America, South American, Europe, and Asia. To learn more, visit www.clinipace.com.
Media Contact Sandra Parrish Woodlief 919-797-9480; [email protected]
